Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/127
A61K-031/335
출원번호
US-0196123
(2005-08-03)
등록번호
US-8298573
(2012-10-30)
발명자
/ 주소
Zhang, Jia-Ai
Ugwu, Sydney
Ma, Lan
Anyarambhatla, Gopal
Ahmad, Imran
출원인 / 주소
Zhang, Jia-Ai
대리인 / 주소
Wood, Phillips, Katz, Clark & Mortimer
인용정보
피인용 횟수 :
0인용 특허 :
33
초록
The invention provides a formulation of one or more antineoplastic drugs encapsulated in liposomes including at least a lipid fraction in addition to the antineoplastic drug, wherein the composition is stable in an aqueous solution at room temperature.
대표청구항▼
1. A formulation of paclitaxel encapsulated in a liposome, wherein the liposome comprises a lipid fraction, and the lipid fraction comprises 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), tetramyristoyl cardiolipin (CL) and cholesterol (CH), wherein the DOPC comprises between about 90 percent to a
1. A formulation of paclitaxel encapsulated in a liposome, wherein the liposome comprises a lipid fraction, and the lipid fraction comprises 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), tetramyristoyl cardiolipin (CL) and cholesterol (CH), wherein the DOPC comprises between about 90 percent to about 92 percent of the lipid fraction, wherein the amount of the lipid fraction is at least about 3.5% w/v of the formulation and not more than about 8.5% w/v of the formulation, and wherein the liposomes have a mean size of 50 to 200 nm, and wherein said formulation is stable in an aqueous solution at room temperature for at least three days. 2. The formulation of claim 1, wherein the concentration of CH is between about 1 mg/ml and about 2 mg/ml, the concentration of CL is between about 2 mg/ml and about 8 mg/ml; and the concentration of DOPC is between about 44 mg/ml and about 74 mg/ml of the formulation. 3. The formulation of claim 1, wherein the paclitaxel is selected from a group consisting of 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10- desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7-glutarylpaclitaxel, 7-N-N-dimethylglycylpaclitaxel, 7-L-alanylpaclitaxel and mixtures thereof. 4. The formulation of claim 1, wherein the formulation does not contain visible paclitaxel drug crystal or precipitate, as confirmed by microscopic examination. 5. The formulation of claim 1, wherein the formulation is free of paclitaxel drug crystal and precipitate. 6. The formulation of claim 1, wherein at least 75 percent of the paclitaxel is encapsulated in the liposome. 7. The formulation of claim 1, wherein at least 85 percent of the paclitaxel is encapsulated in the liposome. 8. The formulation of claim 1, wherein at least 90 percent of the paclitaxel is encapsulated in the liposome. 9. The formulation of claim 1, wherein the ratio of lipid fraction to the paclitaxel is between about 10:1 and about 70:1 by molar ratio. 10. The formulation of claim 1, further comprising D-alpha tocopherol acid succinate. 11. The formulation of claim 1, further comprising a lyoprotectant. 12. The formulation of claim 11, wherein the lyoprotectant comprises one or more sugars selected from a group consisting of sucrose, mannitol, trehalose, maltose, lactose, glucose, dextran, aminoglycosides, streptomycin and combinations thereof. 13. The formulation of claim 1, wherein the liposomes have been sterile-filtered. 14. The formulation of claim 13, wherein the liposomes have been sterile-filtered through a 0.22 micron filter. 15. The formulation of claim 1, wherein the liposomes have a mean size of 100-180 nm. 16. The formulation of claim 1, wherein the liposomes have a mean size of 120-160 nm. 17. The formulation of claim 1, wherein the liposomes are in a lyophilized form. 18. A method of making the formulation of claim 1, comprising dissolving 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), tetramyristoyl cardiolipin (CL), cholesterol (CH) and the paclitaxel in an organic solvent, wherein the DOPC comprises between about 90 percent to about 92 percent of the lipid fraction. 19. The method of claim 18, wherein the DOPC, CH and CL has a molar ratio of DOPC:CH:CL of between about 92:0:8 and about 90:5:5. 20. The method of claim 18, wherein the organic solvent is selected from a group consisting of methylene chloride, ethanol, methyl acetate and ethyl formate. 21. The method of claim 18, further comprising an, antioxidant. 22. The method of claim 18, further comprising substantially removing the organic solvent to form a dried lipid residue. 23. The method of claim 18, further comprising hydrating the lipid residue with an aqueous solution to form liposomes. 24. The method of claim 23, wherein the hydration further comprises mixing the lipid residue with the aqueous solution to form liposomes. 25. The method of claim 18, further comprising adding a lyoprotectant. 26. The metliod of claim 25, wherein the lyoprotectant is selected from a group consisting of sucrose, mannitol, trehalose, maltose, lactose, glucose, dextran, aminoglycosides, streptomycin and combinations thereof. 27. The method of claim 18, further comprising adding a tonicity adjuster. 28. The method of claim 23, further comprising sterile filtering the liposomes. 29. The method of claim 28, wherein the filtering is through a 0.22 micron filter. 30. The method of claim 23, further comprising lyophilizing the liposomes. 31. The method of claim 23, further comprising reconstituting the liposomes in a polar solvent. 32. A method of administering the formulation of claim 1, the method comprising administering to a human patient said formulation over a period of about 90 minutes to about 180 minutes, wherein said formulation comprises from about 325 mg/m2 to about 375 mg/m2 of paclitaxel. 33. The method of claim 32 wherein said paclitaxel is selected from the group consisting of paclitaxel, 7-epipaclitaxel, t-acetyl paclitaxel, 10-desacetyl-paclitaxel, 10-desacetyl-7-epipaclitaxel, 7-xylosylpaclitaxel, 10-desacetyl-7-glutarylpaclitaxel, 7-N,N-dimethylglycylpaclitaxel, 7-L-alanylpaclitaxel, taxotere and mixtures thereof. 34. The method of claim 32 wherein said formulation further comprises a tocopherol. 35. The method of claim 32 wherein said formulation comprises 325 mg/m2 of paclitaxel. 36. The method of claim 32 wherein said formulation is administered by intravenous infusion. 37. The method of claim 32 wherein said formulation is administered over a period of about 90 minutes. 38. The method of claim 32 wherein the patient is suffering from cancer. 39. The method of claim 38 wherein said cancer is selected from the group consisting of breast, ovary and colon.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Easton PA), Alpha tocopherol-based vesicles.
Kohn Elise C. (Olney MD) Reed Eddie (Germantown MD) Liotta Lance A. (Potomac MD), Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs.
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Easton PA) Suddith Robert L. (Robbinsville N, Composition using salt form of organic acid derivative of alpha-tocopheral.
Janoff Andrew S. (Yardley PA) Cullis Pieter R. (Vancouver CAX) Bally Marcel B. (Vancouver NJ CAX) Fountain Michael W. (Griggstown NJ) Ginsberg Richard S. (Monroe NJ) Hope Michael J. (Vancouver CAX) M, Dehydrated liposomes.
Stella Valentino J. (Lawrence KS) Mathew Abraham E. (Lenexa KS), Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof.
Janoff Andrew S. (Yardley PA) Popescu Mircea C. (Plainsboro NJ) Alving Carl R. (Bethesda MD) Fountain Michael W. (Farragut TN) Lenk Robert P. (The Woodlands TX) Ostro Marc J. (Princeton NJ) Tremblay , Drug preparations of reduced toxicity.
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Cupertino CA) Suddith Robert L. (Robbinsvill, Entrapment of water-insoluble compound in alpha tocopherol-based vesicles.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv MD ILX) Husain Syed R. (Gaithersburg MD), Liposome encapsulated taxol and a method of using the same.
Rahman Aquilur (Gaithersburg MD) Rafaeloff Rafael (Tel-Aviv ILX) Husain Syed Rafat (Gaithersburg MD), Liposome encapsulated toxol and a method of using the same.
Janoff Andrew S. (Yardley PA) Bolcsak Lois E. (Lawrenceville NJ) Weiner Alan L. (Lawrenceville NJ) Tremblay Paul A. (Hamilton NJ) Bergamini Michael V. W. (Easton PA), Method for preparing alpha-tocopherol vesicles.
Stogniew Martin ; Alberts David S. ; Kaplan Edward H., Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.